Celgene Corporation (CELG) Release: Clinical Study In The Journal Of Clinical Oncology Reports Patients With Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID With Standard R-CHOP Achieved 98% Overall Response Rate And 80% Complete Response Rate
8/19/2014 10:12:54 AM
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that results of a study evaluating the combination of REVLIMID® (lenalidomide) with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP) in untreated diffuse large b-cell lymphoma (DLBCL) were published online ahead of print in the Journal of Clinical Oncology.
Help employers find you! Check out all the jobs and post your resume.
comments powered by